| Not Yet Recruiting | Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax NCT07478471 | Emergent BioSolutions | — |
| Not Yet Recruiting | Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposur NCT02177721 | Emergent BioSolutions | Phase 4 |
| Recruiting | Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellul NCT07051525 | Peter MacCallum Cancer Centre, Australia | N/A |
| Recruiting | Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients NCT07110636 | Karius, Inc. | N/A |
| Recruiting | Therapeutic Options for CRAB NCT06440304 | Clinical Hospital Centre Zagreb | Phase 4 |
| Recruiting | Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment NCT06427317 | Imperial College London | — |
| Completed | Microbiome Analysis of Dental Biofilm on High-Density Polytetrafluoroethylene Membranes Used in Socket Preserv NCT06694844 | Marija Čandrlić | N/A |
| Withdrawn | A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS NCT05340257 | GlaxoSmithKline | Phase 2 |
| Recruiting | Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis NCT06451172 | Eye & ENT Hospital of Fudan University | EARLY_Phase 1 |
| Active Not Recruiting | Challenge Non-Typhoidal Salmonella (CHANTS) Study NCT05870150 | Imperial College Healthcare NHS Trust | N/A |
| Completed | TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era NCT05752019 | Erasmus Medical Center | — |
| Completed | Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial NCT04620486 | Massachusetts General Hospital | N/A |
| Completed | Drug-drug Interaction Study of Gepotidacin NCT04493931 | GlaxoSmithKline | Phase 1 |
| Completed | Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects NCT04079790 | GlaxoSmithKline | Phase 1 |
| Unknown | Gram-negative Bacilli and MRSA Screening in ICU in China NCT04310722 | Sir Run Run Shaw Hospital | — |
| Unknown | Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients NCT03557840 | Paul M. Tulkens | N/A |
| Completed | Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection NCT03568942 | GlaxoSmithKline | Phase 2 |
| Completed | Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impa NCT03562117 | GlaxoSmithKline | Phase 1 |
| Completed | Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixim NCT03408392 | GlaxoSmithKline | Phase 1 |
| Withdrawn | A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fas NCT03329547 | GlaxoSmithKline | Phase 1 |
| Completed | Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference P NCT03150082 | GlaxoSmithKline | Phase 1 |
| Unknown | Thermal Images on Smartphones to Diagnose Bacterial Pneumonia in Children in Pakistan NCT02908399 | Massachusetts General Hospital | N/A |
| Completed | To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 NCT02853435 | GlaxoSmithKline | Phase 1 |
| Completed | Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With NCT02729038 | GlaxoSmithKline | Phase 1 |
| Terminated | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat NCT02751424 | GlaxoSmithKline | Phase 1 |
| Completed | Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia NCT02778672 | Boston University | — |
| Completed | Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, Indi NCT02381431 | Massachusetts General Hospital | N/A |
| Completed | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed NCT02339155 | Emergent BioSolutions | Phase 4 |
| Completed | Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections NCT02292498 | Massachusetts General Hospital | N/A |
| Withdrawn | A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and E NCT01953809 | GlaxoSmithKline | Phase 1 |
| Withdrawn | A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in NCT01803399 | GlaxoSmithKline | Phase 1 |
| Completed | Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute NCT02045797 | GlaxoSmithKline | Phase 2 |
| Completed | Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in H NCT02045849 | GlaxoSmithKline | Phase 1 |
| Completed | To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944 NCT01934205 | GlaxoSmithKline | Phase 1 |
| Terminated | A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunte NCT01818011 | GlaxoSmithKline | Phase 1 |
| Completed | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous a NCT01663389 | GlaxoSmithKline | Phase 1 |
| Completed | A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy NCT01648179 | GlaxoSmithKline | Phase 1 |
| Completed | WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics NCT01587768 | GlaxoSmithKline | — |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Hea NCT01610388 | GlaxoSmithKline | Phase 1 |
| Completed | Amoxicillin Bioequivalence Study Brazil - Fast NCT01431989 | GlaxoSmithKline | Phase 1 |
| Completed | A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of NCT01262885 | GlaxoSmithKline | Phase 1 |
| Withdrawn | A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacoki NCT01039610 | GlaxoSmithKline | Phase 1 |
| Suspended | In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance NCT01132417 | King Faisal University | — |
| Completed | A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in H NCT00896558 | GlaxoSmithKline | Phase 1 |
| Completed | Relative Bioavailability Study in Healthy Subjects NCT00924911 | GlaxoSmithKline | Phase 1 |
| Completed | Single Dose Escalation First Time in Human PK Study NCT00828867 | GlaxoSmithKline | Phase 1 |
| Completed | Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus NCT00539994 | GlaxoSmithKline | Phase 2 |
| Completed | To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single Doses Of GSK945237 In Healthy Su NCT00517673 | GlaxoSmithKline | Phase 1 |
| Terminated | Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416 NCT00680485 | GlaxoSmithKline | Phase 1 |
| Completed | A Three-Part Study Of GSK580416 In Healthy Subjects NCT00427141 | GlaxoSmithKline | Phase 1 |
| Completed | Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COP NCT00259909 | GlaxoSmithKline | — |
| Completed | Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg) NCT00358371 | GlaxoSmithKline | Phase 1 |